EyeGene Inc. (KOSDAQ: 185490)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,640.00
+5.00 (0.19%)
Jan 21, 2025, 9:00 AM KST
-20.36%
Market Cap 70.28B
Revenue (ttm) 3.26B
Net Income (ttm) -14.09B
Shares Out 27.03M
EPS (ttm) -658.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,396
Average Volume 31,591
Open 2,630.00
Previous Close 2,635.00
Day's Range 2,570.00 - 2,695.00
52-Week Range 2,430.00 - 4,720.00
Beta 1.51
RSI 40.77
Earnings Date Mar 14, 2025

About EyeGene

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company’s products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculos... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 41
Stock Exchange KOSDAQ
Ticker Symbol 185490
Full Company Profile

Financial Performance

In 2023, EyeGene's revenue was 3.13 billion, a decrease of -40.96% compared to the previous year's 5.29 billion. Losses were -21.11 billion, -18.68% less than in 2022.

Financial Statements

News

There is no news available yet.